CLDX
Celldex Therapeutics, Inc.
There isn't enough reported data to score CLDX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CLDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
CLDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLDX PE Valuation
CLDX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CLDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CLDX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CLDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.65 | -$0.39 |
| Q2 2023 | -$2.41 | -$0.27 |
| Q1 2023 | -$2.53 | -$0.82 |
| Q4 2022 | -$2.40 | -$0.76 |
| Q3 2022 | -$2.26 | -$0.50 |
| Q2 2022 | -$2.14 | -$0.47 |
| Q1 2022 | -$1.71 | +$0.12 |
| Q4 2021 | -$1.64 | +$0.50 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 263% for CLDX versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
CLDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $22K | -97% |
| Q1 2026 | $15K | -98% |
| Q4 2025 | $121K | -90% |
| Q2 2025 | $730K | -71% |
| Q1 2025 | $695K | +346% |
| Q4 2024 | $1.2M | -72% |
| Q3 2024 | $3.2M | +110% |
| Q2 2024 | $2.5M | +832% |
CLDX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -366468% | -357721 points |
| Q1 2026 | -562900% | -553873 points |
| Q4 2025 | -72027% | -67259 points |
| Q2 2025 | -8748% | -6893 points |
| Q1 2025 | -9027% | +17004 points |
| Q4 2024 | -4768% | -3615 points |
| Q3 2024 | -1634% | +1085 points |
| Q2 2024 | -1854% | +10536 points |
CLDX's operating margin was −366468% last quarter, down 357441 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CLDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CLDX on profitability, with a higher operating margin.
CLDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$66.7M | -$17.6M |
| Q2 2026 | -$60.6M | -$15.9M |
| Q1 2026 | -$67.2M | -$12.6M |
| Q4 2025 | -$65.2M | -$32M |
| Q3 2025 | -$49.1M | +$6.8M |
| Q2 2025 | -$44.7M | -$15.1M |
| Q1 2025 | -$54.6M | -$13.7M |
| Q4 2024 | -$33.2M | -$33K |
CLDX has burned cash in almost every quarter: −$260M over the past year, against −$182M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CLDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +691K shares |
| 1 year | +67% | +31.6M shares |
| 3 years | +351% | +61.1M shares |
CLDX has 79M diluted shares, up 67% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CLDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CLDX Net Leverage
CLDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CLDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 11.5 | Oversold |
CLDX's weekly RSI is 41 (neutral) and its Stochastic is 12 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CLDX PE vs Healthcare Sector
CLDX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CLDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.7 | 4.1% below |
| 20 week MA | $35.1 | 19% below |
| 50 week MA | $31.6 | 9.7% below |
| 100 week MA | $27.1 | 5.2% above |
| 200 week MA | $31.2 | 8.4% below |
CLDX's trend is mixed: it's above one of its five weekly moving averages, and 8.4% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CLDX on trend strength, trading above more of its moving averages.
CLDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.22 | $17.5 | +687% |
| 2021 | $17.5 | $42.0 | +140% |
| 2022 | $42.0 | $44.1 | +5% |
| 2023 | $44.1 | $39.7 | -10% |
| 2024 | $39.7 | $25.4 | -36% |
| 2025 | $25.4 | $26.4 | +4% |
| 2026 YTD | $26.4 | $28.5 | +8.1% |
CLDX has finished higher in four of the last six years, two of them by more than 50%. It's up 8.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CLDX on returns for 2026, with the stronger performance.